Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05246839 · ClinicalTrials.gov registry record
Informed Choice - Compass
A clinical trial, sponsored by Exact Sciences Corporation.
- Terminated
- Registry status
- 1,823
- Enrollment target
NCT05246839: Clinical Trial study, sponsored by Exact Sciences Corporation.
NCT05246839 is a clinical trial that was terminated before completion, run by Exact Sciences Corporation. The registered enrollment target is 1,823 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05246839 was terminated before completion, sponsored by Exact Sciences Corporation.
- TERMINATED
- Registry status
- 1,823 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the impact of a theoretically grounded video that includes information about CRC screening modality choices on CRC screening rates and time adherent to CRC guidelines. The results will not be posted because the study terminated early and the primary endpoint was not analyzed.
Primary Outcome
To evaluate the impact of a theoretically grounded video that includes information about CRC screening modality choices (colonoscopy, FIT, and Cologuard) on CRC screening rates and the proportion of time adherent to CRC guidelines.
Interventions
- BEHAVIORAL Brief Video
- BEHAVIORAL Brief Video Plus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,823 participants |
| Start Date | 2022-04-28 |
| Est. Completion | 2025-01-31 |
Why NCT05246839 stopped before completion
NCT05246839 is an observational study that tracks outcomes without assigning an intervention. Its 1,823 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Brief Video is the first listed.
NCT05246839 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05246839 about?
NCT05246839 is a clinical study titled "Informed Choice - Compass". The primary objective of this study is to evaluate the impact of a theoretically grounded video that includes information about CRC screening modality choices on CRC screening rates and time adherent to CRC guidelines. The results will not be posted because the study terminated early and the primary...
What is the current status of trial NCT05246839?
This trial is currently terminated. The enrollment target is 1,823 participants. The study started on 2022-04-28. Estimated completion is 2025-01-31.
What interventions are being tested in trial NCT05246839?
The interventions under investigation include: Brief Video (BEHAVIORAL), Brief Video Plus (BEHAVIORAL).
Who is sponsoring clinical trial NCT05246839?
This trial is sponsored by Exact Sciences Corporation, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07104240 · 1,836 participants · NA
A Vaccine Promotion Package (TweenVax) to Improve Adolescent HPV Vaccination, TweenVax Trial
- NCT05897788 · 1,808 participants · NA
Text-Messaging Telehealth and Contingency Management for Opioid Use Disorder Treatment Engagement
- NCT06740630 · 1,840 participants · Phase 3
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
- NCT05935007 · 1,805 participants
Aveir DR Real-World Evidence Post-Approval Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI